[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355031-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355031-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","development-of-a-lactate-metabolism-signature-for-predicting-homologous-recombination-repair-status-in-breast-cancer","Development of a lactate metabolism signature for predicting homologous recombination repair status in breast cancer","","Homologous recombination repair deficiency (HRD) serves as a critical biomarker for breast cancer patients targeted with PARP inhibitors, yet HRD detection typically requires comprehensive genomic profiling. This study refines published lactate metabolism gene sets to build an HRD-related lactate signature using LASSO regression. The resulting two-gene model (HPDL, SLC16A8) stratifies TCGA breast cancer cohorts into prognostic groups, with high-risk tumors showing immunosuppressive features, higher lactate scores, and distinct drug sensitivities.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/development-of-a-lactate-metabolism-signature-for-predicting-homologous-recombination-repair-status-in-breast-cancer/355031/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/development-of-a-lactate-metabolism-signature-for-predicting-homologous-recombination-repair-status-in-breast-cancer/355031.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does this study address about HRD in breast cancer?","Question",{"text":63,"@type":64},"It tests whether metabolic signatures based on lactate metabolism can indicate HRD status, potentially reducing reliance on comprehensive genomic analysis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the lactate metabolism signature constructed?",{"text":68,"@type":64},"Published lactate metabolism gene sets were refined and used to develop an HRD-related lactate signature with LASSO regression.",{"name":70,"@type":61,"acceptedAnswer":71},"What biological and clinical differences were observed between high- and low-risk groups?",{"text":72,"@type":64},"The high-risk group showed significantly worse overall survival, immunosuppressive immune features (e.g., reduced CD8+ and follicular helper T cells, increased M2 macrophages), higher lactate metabolism scores, and different sensitivities to anticancer drugs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355031,1790198012,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDevelopment of a lactate metabolism signature for predicting homologous recombination repair status in breast cancer  \nYejue Lin1,4, Lingting Jiang2,4, Shiyao Hu3, Yun Zhang2􀀍 & Ming Luo1􀀍  \nHomologous recombination repair deficiency (HRD) is a key biomarker for targeting breast cancer (BC) with PARP inhibitors (e.g., olaparib), but its detection usually requires a comprehensive genomic analysis. We explored whether metabolic signatures could indicate HRD status. We refined published lactate metabolism gene sets to develop an HRD-related lactate signature using least absolute shrinkage and selection operator (LASSO) regression. Using this signature, we stratifiedmore than1000 TCGA BC samples into high-and low-risk groups. We compared tumor immune-cell composition between groups using CIBERSORT and assessed associations with sensitivity to over 500 anticancer drugs using the GDSC2 and CTRP2 databases. A two-gene lactate metabolism signature (HPDL and SLC16A8) was constructed to stratify patients into high-and low-risk prognostic groups. The high-risk group had significantly worse overall survival. High-risk tumors presented immunosuppressive features (reduced CD8+ T cells and follicular helper T cells, and increased M2 macrophages) and higher lactate metabolism scores than low-risk tumors did. Drug response analysis revealed that the low-risk group was more sensitive to several targeted agents, notably Nutlin-3 (an MDM2–p53 pathway inhibitor). We established a novel lactate metabolism signature that is predictive of prognosis and HRD in patients withBC. This signature provides mechanistic insight into the link between tumor metabolism and DNA repair and may help guide targeted therapy selection (e.g., MDM2 inhibitors) forbreast cancer patients.  \nKeywords Breast cancer, Lactate metabolism, Homologous recombination deficiency (HRD), PARP inhibitor, Nutlin-3, Targeted therapy  \nBreast cancer (BC) is the most common malignancy in women and is a leading cause of cancer-related mortality1. Although BC generally has a better OS than other cancer types do, the high heterogeneity of BC contributes to the failure of many stratification methods toprovide proper treatment and prognostic information, leading to inadequate or excessive treatment. Therefore, it is necessary to develop novel and reliable prognostic markers that can enable more accurate stratification of BC subtypes, not limited to estrogen receptor (ER), progesterone receptor (PR) and HER2 status estimation, which can better guide individualized treatment decisions.  \nCancers are addicted to aerobic glycolysis even in the presence of oxygen; this abnormal metabolism is also known as the “Warburg effect”. Lactate, which has long been neglected as a waste product derived from glycolysis, is now regarded as an important carbon source for cellular metabolism in cancer. It plays a key role in tumor development, metastasis, immunosuppression, and therapeutic resistance via a novel mechanism called lysine lactylation. Recently, Zong et al.2 reported that alanyl-tRNA synthetase (AARS1) is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis. In addition, Chen et al.3 reported that lactate-driven lactylation of Nijmegen breakage syndrome 1 (NBS1) at lysine 388 (K388) promotes homologous recombination (HR)-mediated DNA repair. A reduction in lactate can inhibit NBS1 K388 lactylation, decrease DNA repair efficacy and overcome resistance to chemotherapy. Double-strand breaks (DSBs) are the most  \n1Department of General Surgery, First Affiliated Hospital of Huzhou University, After Square Road 158\\#, Huzhou 313000, Zhejiang, China. 2Haiyan People’s Hospital, Jiaxing University, Jiaxing 314300, Zhejiang, China. 3Department of Breast Surgery and Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. 4Yejue Lin and Lingtian ","cbCaid1uhUZzhjJZ","https://ap.wps.com/l/cbCaid1uhUZzhjJZ","pdf",1658396,"English","# Materials and methods\n## Somatic mutation data for BC samples","[{\"question\":\"What question does this study address about HRD in breast cancer?\",\"answer\":\"It tests whether metabolic signatures based on lactate metabolism can indicate HRD status, potentially reducing reliance on comprehensive genomic analysis.\"},{\"question\":\"How was the lactate metabolism signature constructed?\",\"answer\":\"Published lactate metabolism gene sets were refined and used to develop an HRD-related lactate signature with LASSO regression.\"},{\"question\":\"What biological and clinical differences were observed between high- and low-risk groups?\",\"answer\":\"The high-risk group showed significantly worse overall survival, immunosuppressive immune features (e.g., reduced CD8+ and follicular helper T cells, increased M2 macrophages), higher lactate metabolism scores, and different sensitivities to anticancer drugs.\"}]","Development of a lactate metabolism signature for predicting homologous recombination repair status in breast cancer | PDF",1790115499,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/579379903aa5c4e71539f24bc72d85c7.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/672ae540a334c4367258566a3251c06a.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c895ae90359e951e8e3880fa9d223c32.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbecf61d78fed7401bd713dd1fb4d6e7.webp",980,1287]